THE ASTHMA RELIEF CAMPAIGN PROJECT (NIGERIA) AND THE GLOBAL ALLERGY AND AIRWAYS PATIENT PLATFORM REQUEST GSK FOR SUPPORT FOR ASTHMA PATIENTS IN NIGERIA DUE TO THE DIFFICULTIES IN ACCESS TO INHALERS.

The Global Allergy & Airways Patient Platform (GAAPP), the Asthma Relief Campaign Project (ASMARCAP), following the recent Global Respiratory Summit 2023 in Milan, wants to bring attention to the challenges faced by asthma patients in Nigeria since GlaxoSmithKline’s withdrawal from the country.

GSK Ventolin Inhalers have been the primary first aid medication for 95% of asthma patients in Nigeria. Since GSK´s departure from Nigeria, the cost of these inhalers has surged from 2000 Naira to 10,000 Naira and above, significantly burdening those affected. Asthma is a prevalent chronic condition affecting millions of individuals, including school-age children. Proper education about asthma empowers them to lead healthier lives and creates a safer, more informed school environment.

In light of these circumstances, we would like to request the following:

  • Donation of Inhalers: If possible, we kindly request GlaxoSmithKline to consider donating inhalers for an essential initiative—Asthma Education in schools. We are embarking on a nationwide School Asthma Awareness campaign, and your support in providing inhalers would be invaluable.
  • Educational Materials: We would also like to propose the creation and distribution of informative brochures, posters, and digital resources to students, teachers, parents, and guardians to raise awareness about asthma and its management.

You can download the full letter in English:

Download the letter in English

if you have any inquiries, feel free to contact us at info@gaapp.org or call us at (+43) 6767534200